Navigation Links
VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
Date:11/19/2009

SAN DIEGO, Nov. 19 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions. The VerifyNow P2Y12 Test is used to measure the antiplatelet effect of medications, such as clopidogrel (Plavix®), that reduce platelet reactivity by blocking the platelet P2Y12 receptor.

The POPular study is the first head-to-head comparison of multiple platelet function tests in predicting adverse events in patients undergoing elective coronary stenting. The study investigators mentioned that many of the tests for platelet reactivity evaluated in the study are either labor-intensive, have significant time constraints, or cannot be performed at the point-of-care. The investigators noted that the VerifyNow System does not have these limitations. The investigators also speculated that recent data may soon make platelet reactivity testing a routine clinical tool.

"We are at a time when much attention has been drawn to antiplatelet medications, such as Plavix, and understanding the variability in patients' response to these medications. For example, patients who use certain heartburn medications or patients with a specific genetic disposition may not receive the desired platelet inhibiting effect of Plavix. These are only two of the many factors that may contribute to the variability in response to these life-saving medications. The VerifyNow P2Y12 Test can assist physicians by providing a direct measure of the antiplatelet effect in each patient so they can make more informed treatment decisions," said Timothy Still, president and CEO of Accumetrics.

The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including aspirin, P2Y12 inhibitors [e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)], and GP IIb/IIIa inhibitors [e.g. abciximab (ReoPro®) and eptifibatide (Integrilin®)], the VerifyNow System provides a valuable tool to help physicians make more informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company.

    CONTACT:
    Megan Rusnack
    Lippert/Heilshorn & Associates
    212-838-3777
    mrusnack@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com

SOURCE Accumetrics, Inc.


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
5. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
6. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
9. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
10. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):